TISIDB

Summary
Symbol	CLEC7A
Name	C-type lectin domain family 7, member A
Aliases	dectin-1; hDectin-1; CD369; CLECSF12; C-type (calcium dependent, carbohydrate-recognition domain) lectin, su ......
Chromosomal Location	12p13.2-p12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Single-pass type II membrane protein ; SUBCELLULAR LOCATION: Isoform 5: Cytoplasm.; SUBCELLULAR LOCATION: Isoform 6: Cytoplasm ; SUBCELLULAR LOCATION: Isoform 7: Cytoplasm
Domain	PF00059 Lectin C-type domain
Function	Lectin that functions as pattern receptor specific for beta-1,3-linked and beta-1,6-linked glucans, such as cell wall constituents from pathogenic bacteria and fungi. Necessary for the TLR2-mediated inflammatory response and for TLR2-mediated activation of NF-kappa-B. Enhances cytokine production in macrophages and dendritic cells. Mediates production of reactive oxygen species in the cell. Mediates phagocytosis of C.albicans conidia. Binds T-cells in a way that does not involve their surface glycans and plays a role in T-cell activation. Stimulates T-cell proliferation (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0001562 response to protozoan GO:0002218 activation of innate immune response GO:0002220 innate immune response activating cell surface receptor signaling pathway GO:0002221 pattern recognition receptor signaling pathway GO:0002223 stimulatory C-type lectin receptor signaling pathway GO:0002238 response to molecule of fungal origin GO:0002263 cell activation involved in immune response GO:0002366 leukocyte activation involved in immune response GO:0002429 immune response-activating cell surface receptor signaling pathway GO:0002757 immune response-activating signal transduction GO:0002758 innate immune response-activating signal transduction GO:0002764 immune response-regulating signaling pathway GO:0002768 immune response-regulating cell surface receptor signaling pathway GO:0006909 phagocytosis GO:0006910 phagocytosis, recognition GO:0007159 leukocyte cell-cell adhesion GO:0008037 cell recognition GO:0009620 response to fungus GO:0009743 response to carbohydrate GO:0009756 carbohydrate mediated signaling GO:0031349 positive regulation of defense response GO:0042110 T cell activation GO:0042832 defense response to protozoan GO:0045088 regulation of innate immune response GO:0045089 positive regulation of innate immune response GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0071216 cellular response to biotic stimulus GO:0071226 cellular response to molecule of fungal origin GO:0071322 cellular response to carbohydrate stimulus GO:0071593 lymphocyte aggregation GO:0098542 defense response to other organism
Molecular Function	GO:0008329 signaling pattern recognition receptor activity GO:0030246 carbohydrate binding GO:0038187 pattern recognition receptor activity GO:0042287 MHC protein binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04145 Phagosome
Reactome	R-HSA-5621481: C-type lectin receptors (CLRs) R-HSA-5607764: CLEC7A (Dectin-1) signaling R-HSA-168256: Immune System R-HSA-168249: Innate Immune System

Summary
Symbol	CLEC7A
Name	C-type lectin domain family 7, member A
Aliases	dectin-1; hDectin-1; CD369; CLECSF12; C-type (calcium dependent, carbohydrate-recognition domain) lectin, su ......
Chromosomal Location	12p13.2-p12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CLEC7A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between CLEC7A and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
28394331	Pancreatic Ductal Adenocarcinoma	Inhibit immunity	We found that dectin 1 is highly expressed on macrophages in pancreatic ductal adenocarcinoma (PDA). Dectin 1 ligation accelerated the progression of PDA in mice, whereas deletion of Clec7a-the gene encoding dectin 1-or blockade of dectin 1 downstream signaling was protective. We found that dectin 1 can ligate the lectin galectin 9 in mouse and human PDA, which results in tolerogenic macrophage programming and adaptive immune suppression. Upon disruption of the dectin 1-galectin 9 axis, CD4+ and CD8+ T cells, which are dispensable for PDA progression in hosts with an intact signaling axis, become reprogrammed into indispensable mediators of anti-tumor immunity.
28295265	Melanoma	Promote immunity (T cell function)	In vivo, Dectin-1-mediated Card9 activation after vaccination drives both expansion and activation of Ag-specific CTLs, resulting in long-lasting CTL responses that are sufficient to protect mice from tumor challenge. This Dectin-1-induced antitumor immune response was independent of NK cell function and completely abrogated in Card9-deficient mice.
23280601	colon carcinoma	Promote immunity	The therapeutic response of orally administered MD-Fraction was associated with (i) induced systemic tumor-antigen specific T cell response via dectin-1-dependent activation of DCs, (ii) increased infiltration of the activated T cells into the tumor and (iii) decreased number of tumor-caused immunosuppressive cells such as regulatory T cells and myeloid-derived suppressor cells

Summary
Symbol	CLEC7A
Name	C-type lectin domain family 7, member A
Aliases	dectin-1; hDectin-1; CD369; CLECSF12; C-type (calcium dependent, carbohydrate-recognition domain) lectin, su ......
Chromosomal Location	12p13.2-p12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CLEC7A in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CLEC7A
Name	C-type lectin domain family 7, member A
Aliases	dectin-1; hDectin-1; CD369; CLECSF12; C-type (calcium dependent, carbohydrate-recognition domain) lectin, su ......
Chromosomal Location	12p13.2-p12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CLEC7A in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.092	0.835
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.202	0.888
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.009	0.993
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.338	0.434
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.243	0.872
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.449	0.831
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.066	0.891
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.341	0.783
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.532	0.699
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.097	0.406
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.346	0.518
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.078	0.682

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CLEC7A in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CLEC7A
Name	C-type lectin domain family 7, member A
Aliases	dectin-1; hDectin-1; CD369; CLECSF12; C-type (calcium dependent, carbohydrate-recognition domain) lectin, su ......
Chromosomal Location	12p13.2-p12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CLEC7A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CLEC7A
Name	C-type lectin domain family 7, member A
Aliases	dectin-1; hDectin-1; CD369; CLECSF12; C-type (calcium dependent, carbohydrate-recognition domain) lectin, su ......
Chromosomal Location	12p13.2-p12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CLEC7A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CLEC7A. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CLEC7A
Name	C-type lectin domain family 7, member A
Aliases	dectin-1; hDectin-1; CD369; CLECSF12; C-type (calcium dependent, carbohydrate-recognition domain) lectin, su ......
Chromosomal Location	12p13.2-p12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CLEC7A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CLEC7A
Name	C-type lectin domain family 7, member A
Aliases	dectin-1; hDectin-1; CD369; CLECSF12; C-type (calcium dependent, carbohydrate-recognition domain) lectin, su ......
Chromosomal Location	12p13.2-p12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CLEC7A expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CLEC7A
Name	C-type lectin domain family 7, member A
Aliases	dectin-1; hDectin-1; CD369; CLECSF12; C-type (calcium dependent, carbohydrate-recognition domain) lectin, su ......
Chromosomal Location	12p13.2-p12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CLEC7A and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CLEC7A
Name	C-type lectin domain family 7, member A
Aliases	dectin-1; hDectin-1; CD369; CLECSF12; C-type (calcium dependent, carbohydrate-recognition domain) lectin, su ......
Chromosomal Location	12p13.2-p12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CLEC7A collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CLEC7A